-
News and Events
- News
- Events
- This month on Synapse
- Licensing out - try not to get benched
- SPC manufacturing waiver (Part 3): Notification obligations – Information is power
- COVID-19 and life sciences M&A
- Competition law and coronavirus: what’s the connection?
- National perspectives on the CJEU Bayer decision
- Taking security over IP: counting the cost
- The 2020s: Boris Johnson's decade to prove his life sciences plan
- SPC manufacturing waiver (Part 1)
- Arbitration: considerations for life science companies
- IP, divestments, fragmentation and the future: M&A in life sciences
- Life Sciences Disputes webinar series
- Previous articles
-
Topical Issues
- UK increases scrutiny of tech and life sciences deals
- US buys up entire stock of remdesivir
- Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents
- Private equity investment in life sciences sector
- Patent diary – July 2020: Court refuses to strike out Chiesi's quia timet injunction claim
- Territorial licensing: "start at the end before you begin"
- Too sweet to throw away? Sweetened/carbonated beverages industry law changes in Poland
- Arbitration for life sciences companies
- Legal advice privilege: where are we now?
- Patents diary June 2020: UK Supreme Court holds Regeneron's transgenic mice patents invalid
- SPC manufacturing waiver (Part 2)
- Privacy regulator guidance for life sciences and healthcare in light of COVID-19
- COVID-19 and public compulsory licensing of drugs in Europe
- NHS can procure drugs for use outside of their approved indications if it's cheaper, court says
- Patents diary: April 2020
- Personal protective equipment COVID-19 export restrictions
- The Bolar and related exemptions in Europe: What activity do they cover?
- Right of access to documents in marketing authorisation applications confirmed
- Lower maximum prices of medicines as of April 2020
- Legal uncertainty over EU market access of Swiss medical devices
- Patents diary: March 2020
- Previous articles
- Synapse Toolkit
- Funding life sciences companies
- Duties and liabilities of company directors
- Confidentiality and related protection
- Supplementary protection certificates
- Medical devices
- Biologicals and biosimilars
- Protecting & enforcing IP
- Entering into commercial agreements
- Regulatory compliance
- This month on Synapse
- Licensing out - try not to get benched
- SPC manufacturing waiver (Part 3): Notification obligations – Information is power
- COVID-19 and life sciences M&A
- Competition law and coronavirus: what’s the connection?
- National perspectives on the CJEU Bayer decision
- Taking security over IP: counting the cost
- The 2020s: Boris Johnson's decade to prove his life sciences plan
- SPC manufacturing waiver (Part 1)
- Arbitration: considerations for life science companies
- IP, divestments, fragmentation and the future: M&A in life sciences
- Life Sciences Disputes webinar series
- Previous articles
- Practical Help
- Contact Us
< Back
Synapse Toolkit
Synapse toolkit connects you with the fundamental rules underpinning the life sciences sector. Using our knowledge and experience, we explain here: the regulations and procedures that apply to products; the correct approach to legally secure transactions; and, the protection and enforcement of patents and related rights.